Back | Next |
home / stock / avxl / avxl message board
Subject | By | Source | When |
---|---|---|---|
So when do you think we would hear | Jonjones325 | investorshub | 07/23/2024 4:12:02 AM |
The MAA should have been submitted by now | Steady_T | investorshub | 07/23/2024 2:41:42 AM |
I'm ready to kick myself a few more | bb8675309 | investorshub | 07/23/2024 2:35:59 AM |
Right I guess theres no other choice. | Jonjones325 | investorshub | 07/23/2024 1:51:57 AM |
Who pissed in your Wheaties? | D-Mike | investorshub | 07/23/2024 1:45:53 AM |
Im sure Missling and the team have weighed | tradeherpete | investorshub | 07/23/2024 1:40:12 AM |
You should sell. Then you can sit back | bb8675309 | investorshub | 07/23/2024 1:34:49 AM |
The science will come to light sooner or | Jonjones325 | investorshub | 07/23/2024 12:55:39 AM |
Cool! So he can bring the drug to | ExtremelyBullishZig | investorshub | 07/23/2024 12:05:24 AM |
My questions run to next phase progress.. | tradeherpete | investorshub | 07/22/2024 11:49:24 PM |
Kolbert covered Ariad a stock I made quite | mrplmer | investorshub | 07/22/2024 11:47:53 PM |
So if they submitted to both EMA and | mrplmer | investorshub | 07/22/2024 11:46:18 PM |
Same person, different company, but they've had the | kund | investorshub | 07/22/2024 10:34:38 PM |
Our magic number will be $7.00...then lift-off. | nidan7500 | investorshub | 07/22/2024 9:17:53 PM |
Have to giggle. | LakeshoreLeo1953 | investorshub | 07/22/2024 9:01:19 PM |
This new guy at E. F. Hutton has | WilliamMunny | investorshub | 07/22/2024 8:17:56 PM |
False. Clearly mislabeled. Should be: | Reyeton | investorshub | 07/22/2024 8:10:37 PM |
These strategic hires underscore EF Hutton's commitment to | nidan7500 | investorshub | 07/22/2024 7:53:34 PM |
These strategic hires underscore EF Hutton's commitment to | nidan7500 | investorshub | 07/22/2024 7:49:30 PM |
Excellent! Good to see a Pro recommendation. | williamssc | investorshub | 07/22/2024 7:41:02 PM |
News, Short Squeeze, Breakout and More Instantly...
Anavex Life Sciences Corp. Company Name:
AVXL Stock Symbol:
NASDAQ Market:
Anavex Life Sciences Corp. Website:
Oral, once daily blarcamesine significantly slowed clinical decline for early Alzheimer's disease patients with good comparative safety profile and no associated neuroimaging adverse events Clinical benefit of blarcamesine consistently observed for both 30 mg and 50 mg treatment groups ...
2024-07-18 02:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsyc...